Literature DB >> 33490235

Influence of Alanine Transaminase Levels on Alpha-Fetoprotein for Predicting Hepatocellular Carcinoma in Patients with Hepatitis B Infection.

Jiahao Chen1, Manli Wu2, Jiao Gong1, Zhihuan Liu1, Guowei He1, Huiqing Zhu3, Zhaoxia Li1, Bo Hu1.   

Abstract

PURPOSE: To investigate the influence of alanine transaminase (ALT) on the accuracy of alpha-fetoprotein (AFP) for detecting hepatocellular carcinoma (HCC).
METHODS: This retrospective study recruited 799 patients with HCC, cirrhosis, and chronic hepatitis due to hepatitis B infection and healthy adults between July 2017 and January 2019. Comparisons of the area under the receiver operating characteristic curves (AUCs) for detecting HCC in different ALT levels were calculated.
RESULTS: Serum ALT and gamma-glutamyl transferase levels were significantly associated with elevated AFP in patients without HCC. The AUC of AFP was higher in patients with ALT ≤ 2 upper limit of normal (ULN) than in patients with ALT > 2 ULN (0.806 vs. 0.611, P < 0.001). Nevertheless, there were no significant differences in the AUCs of AFP/(ALT × aspartate aminotransferase (AST)) in patients with ALT ≤ 2 ULN and with ALT > 2 ULN (0.745 vs. 0.769, P = 0.68). AFP/(ALT × AST) was better than AFP in patients with ALT > 2 ULN for detecting HCC (P < 0.001).
CONCLUSIONS: Higher ALT levels might impair the accuracy of AFP for diagnosing HCC. AFP tests showed better accuracy in patients with ALT ≤ 2 ULN whereas the AFP/(ALT × AST) ratio was recommended in patients with elevated ALT levels.
Copyright © 2020 Jiahao Chen et al.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33490235      PMCID: PMC7787738          DOI: 10.1155/2020/2043715

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  24 in total

1.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

2.  Elevated alpha fetoprotein, no hepatocellular carcinoma.

Authors:  Mallikarjun Patil; Keyur A Sheth; Channagiri K Adarsh
Journal:  J Clin Exp Hepatol       Date:  2013-03-05

Review 3.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

4.  Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.

Authors:  Jessica A Davila; Robert O Morgan; Peter A Richardson; Xianglin L Du; Katherine A McGlynn; Hashem B El-Serag
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

5.  Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.

Authors:  Adrian M Di Bisceglie; Richard K Sterling; Raymond T Chung; James E Everhart; Jules L Dienstag; Herbert L Bonkovsky; Elizabeth C Wright; Gregory T Everson; Karen L Lindsay; Anna S F Lok; William M Lee; Timothy R Morgan; Marc G Ghany; David R Gretch
Journal:  J Hepatol       Date:  2005-09       Impact factor: 25.083

Review 6.  Epidemiology and surveillance of hepatocellular carcinoma.

Authors:  Do Young Kim; Kwang-Hyub Han
Journal:  Liver Cancer       Date:  2012-06       Impact factor: 11.740

7.  Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study.

Authors:  B J McMahon; L Bulkow; A Harpster; M Snowball; A Lanier; F Sacco; E Dunaway; J Williams
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

8.  Intrahepatic cholangiocarcinoma arising in chronic viral hepatitis-associated cirrhosis: two transplant cases.

Authors:  D Nart; Y Ertan; E E Pala; M Zeytunlu; M Kilic; F Yilmaz
Journal:  Transplant Proc       Date:  2008-12       Impact factor: 1.066

9.  Relationship of hepatitis B surface antigen to serum alpha-fetoprotein in nonmalignant diseases of the liver.

Authors:  D S Chen; J L Sung
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

10.  An overview of biomarkers for the diagnosis of hepatocellular carcinoma.

Authors:  Mona Abu El Makarem
Journal:  Hepat Mon       Date:  2012-10-20       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.